SAS and Carolina partner to accelerate antiviral drug development

Posted Nov 19, 2021
SAS, a leader in analytics and software services, and the University of North Carolina are teaming up to transform the drug development process to prevent infectious disease threats from turning into a pandemic like COVID-19. The partnership is focused on the work of the University’s Rapidly Emerging Antiviral Drug Development Initiative (READDI). (UNC.edu)

Related: Campus Connections

‘Witness’ Carolina’s role in the Revolutionary War
To commemorate America’s 250th birthday, Wilson Library is hosting a new exhibition. “Witnesses to the Revolution: North Carolina and the War for Independence” explores how...
Wed Aug 19, 2026

UNC students take first-day sips at the Old Well
It’s the first day of classes at Carolina, and as Tar Heels know, that means it’s also time to drink from the Old Well for...
Mon Aug 17, 2026

Nonprofit at UNC pairs those with chronic illnesses with a service dog
UNC’s chapter of Lux’s Purpose was founded this year. Service dogs cost as much as $50,000-$70,000, and there is not a single insurance plan that...
Sun Aug 16, 2026

UNC Gears Up for First Day of Classes
The Chapel Hill summer is wrapping up this weekend, as UNC students return to campus ahead of the first day of class on Monday. “It’s...
Sat Aug 15, 2026